NCT05876065View on ClinicalTrials.gov

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

February 28, 2027

Conditions
Advanced Breast Cancer
Interventions
DRUG

XC

Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days

DRUG

TPC

Any physician's choice as maintenance therapy (except for XC regimen)

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjin Yin

OTHER